Uncategorised - European Medical Journal

IDWeek 2023 Abstract Highlights

They cover key topics, including disparities in sepsis management, methicillin-resistant Staphylococcus aureus decolonization…

Disease X: The Next Pandemic

The idea of preventing diseases before they start was integral to the first presentation, delivered by Aaron Bernstein, National Center…

Scarring Alopecia: Cutting-Edge Approaches

Jerry Shapiro, New York University (NYU) Langone Health, USA, presented on evaluating and diagnosing scarring alopecia…

Efficacy and Safety of Upadacitinib in a Phase II Randomised, Double-Blind, Dose-Ranging Study of Adults with Extensive Non-segmental Vitiligo

Vitiligo is an autoimmune skin disorder that causes depigmentation of the skin and/or leukotrichia of the hair, resulting from the…

Lichen Sclerosus in Prepubertal Males: Breaking the Paradigm

Lichen sclerosus (LS) is a chronic inflammatory condition primarily affecting the genital area, characterised by hypopigmented skin…

A New Landmark for Wellbeing in Psoriasis: The POSITIVE Study

Psoriatic disease is a chronic, inflammatory immune condition affecting more than 40 million individuals worldwide…

The Safety Profile of Biological Agents in Patients with Psoriasis and HIV: A Systematic Review

Patients with HIV and severe psoriasis who require biological agents are thus thought to be at increased risk of adverse events….

Clinical Practice Guideline Updates

Barbara Trautner, Baylor College of Medicine, Houston, Texas, USA, presented the inaugural clinical practice guidelines for treating…

Live Webinar: ECLS with Xenios console | December 12th 7:30 AM - 8:30 AM CET

Join us to get to know Fresenius Medical Care’s ECMO offering – a dedicated technology combining both, heart and lung support in one single platform.

Neurofilament Light Chain Levels Predict Multiple Sclerosis Disability Progression

According to new research, elevation of serum neurofilament light chain, a biomarker of neuroaxonal injury, can predict disability worsening in multiple sclerosis within 1–2 years.